Preoperative Evaluation and Management Practice Questions

Q: Which of the following can be used as a pre-anesthetic medication to decrease secretions and reflux bronchospasm during general anesthesia?

Glycopyrrolate.. ***Glycopyrrolate*** - It is a **quaternary ammonium anticholinergic** that reduces salivary, tracheobronchial, and pharyngeal secretions effectively. - Due to its **limited ability to cross the blood-brain barrier**, it has fewer central nervous system side effects compared to atropine. *Ipratropium* - This medication is a **short-acting muscarinic antagonist** primarily used as a bronchodilator for conditions like asthma and COPD. - While it can reduce secretions, it's typically administered via inhalation for its local bronchodilatory effects and is not a common systemic pre-anesthetic antisialagogue. *Tiotropium* - **Tiotropium** is a **long-acting muscarinic antagonist** used for maintenance treatment of COPD, administered via inhalation. - Its primary role is sustained bronchodilation, and it is not employed as a systemic pre-anesthetic antisialagogue. *Atropine* - While atropine is an antipsychotic that can reduce secretions and counteract **bradycardia**, it readily **crosses the blood-brain barrier**, leading to more central nervous system side effects such as confusion and delirium. - Its use has decreased in favor of agents like glycopyrrolate that have a better side effect profile for reducing secretions in the perioperative setting.

Q: Preanaesthetic medication glycopyrrolate is primarily used for:

Decrease secretion. ***Decrease secretion*** - Glycopyrrolate is an **anticholinergic drug** that primarily works by blocking muscarinic acetylcholine receptors, thereby reducing glandular secretions throughout the body. - This effect includes reducing **salivary**, **bronchial**, and **gastric secretions**, which is beneficial during anesthesia. *Reduce bronchial secretions* - While glycopyrrolate does **reduce bronchial secretions**, this is a specific aspect of its broader effect of decreasing secretions, making "decrease secretion" a more comprehensive answer. - Reducing bronchial secretions helps in maintaining a **clear airway** and preventing atelectasis. *Prevent aspiration* - By decreasing gastric and salivary secretions, glycopyrrolate can indirectly help to **reduce the risk of aspiration** of gastric contents or saliva into the lungs. - However, preventing aspiration is a beneficial **consequence** of reduced secretions, not the direct pharmacological action described as "decrease secretion." *Antisialagogue effect* - The **antisialagogue effect**, which means reducing saliva production, is a prominent action of glycopyrrolate and is part of its overall secretion-decreasing property. - Reducing salivary secretions creates a **dry operative field** during procedures involving the oral cavity or airway.

Question 1

Which of the following can be used as a pre-anesthetic medication to decrease secretions and reflux bronchospasm during general anesthesia?

Accepted Answer

Glycopyrrolate.

Answer

Ipratropium.

Answer

Tiotropium.

Answer

Atropine.

Question 2

Preanaesthetic medication glycopyrrolate is primarily used for:

Accepted Answer

Decrease secretion

Answer

Antisialagogue effect

Answer

Prevent aspiration

Answer

Reduce bronchial secretions

Question 3

What is the most appropriate perioperative management regarding the antihypertensive medication of a 55-year-old male with a history of hypertension who has been taking ACE inhibitors for the past 5 years and is scheduled for elective hernia repair surgery?

Accepted Answer

Continue ACE inhibitors until the morning of surgery

Answer

Switch to a beta-blocker 48 hours before surgery

Answer

No changes needed in his medication regimen

Answer

Discontinue ACE inhibitors 24 hours prior to surgery to avoid hypotension.

Preoperative Evaluation and Management — MCQs

Preoperative Evaluation and Management — MCQs

On this page

Practice by Chapter

Want unlimited practice?